Eupraxia OTC Stock Performance

EPRXF -  USA Stock  

USD 2.30  0.00  0.00%

Eupraxia Pharmaceuticals has performance score of 8 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.1044, which means not very significant fluctuations relative to the market. Let's try to break down what Eupraxia's beta means in this case. As returns on the market increase, Eupraxia Pharmaceuticals returns are expected to increase less than the market. However, during the bear market, the loss on holding Eupraxia Pharmaceuticals will be expected to be smaller as well. Although it is extremely important to respect Eupraxia Pharmaceuticals historical returns, it is better to be realistic regarding the information on equity current trending patterns. The philosophy towards predicting future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By reviewing Eupraxia Pharmaceuticals technical indicators, you can presently evaluate if the expected return of 0.0347% will be sustainable into the future. Eupraxia Pharmaceuticals right now shows a risk of 0.28%. Please confirm Eupraxia Pharmaceuticals standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and expected short fall to decide if Eupraxia Pharmaceuticals will be following its price patterns.

Eupraxia O TC Stock Performance 

 
Refresh
Eupraxia Performance
8 of 100
Compared to the overall equity markets, risk-adjusted returns on investments in Eupraxia Pharmaceuticals are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of rather sound basic indicators, Eupraxia Pharmaceuticals is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders. ...more

Eupraxia Price Channel

Quick Ratio11.87
Fifty Two Week Low1.6393
Fifty Two Week High2.7890

Eupraxia Pharmaceuticals Relative Risk vs. Return Landscape

If you would invest  225.00  in Eupraxia Pharmaceuticals on October 18, 2021 and sell it today you would earn a total of  5.00  from holding Eupraxia Pharmaceuticals or generate 2.22% return on investment over 90 days. Eupraxia Pharmaceuticals is currently producing 0.0347% returns and takes up 0.2778% volatility of returns over 90 trading days. Put another way, 2% of traded otc stocks are less volatile than Eupraxia, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days.
 Daily Expected Return (%) 
      Risk (%) 
Assuming the 90 days horizon Eupraxia Pharmaceuticals is expected to generate 0.35 times more return on investment than the market. However, the company is 2.84 times less risky than the market. It trades about 0.12 of its potential returns per unit of risk. The DOW is currently generating roughly 0.04 per unit of risk.

Eupraxia Pharmaceuticals Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Eupraxia Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Eupraxia Pharmaceuticals, and traders can use it to determine the average amount a Eupraxia Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.125

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative ReturnsEPRXF
Estimated Market Risk
 0.28
  actual daily
 
 2 %
of total potential
 
22
Expected Return
 0.03
  actual daily
 
 0 %
of total potential
 
00
Risk-Adjusted Return
 0.13
  actual daily
 
 8 %
of total potential
 
88
Based on monthly moving average Eupraxia Pharmaceuticals is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Eupraxia Pharmaceuticals by adding it to a well-diversified portfolio.

About Eupraxia Pharmaceuticals Performance

To evaluate Eupraxia Pharmaceuticals OTC Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Eupraxia Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Eupraxia OTC Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Eupraxia Pharmaceuticals stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents Eupraxia's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada. Eupraxia Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange.

Things to note about Eupraxia Pharmaceuticals

Checking the ongoing alerts about Eupraxia Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Eupraxia Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Eupraxia Pharmaceuticals Alerts

Equity Alerts and Improvement Suggestions

Eupraxia Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (19.41 M).
Eupraxia Pharmaceuticals has accumulated about 33.67 M in cash with (11.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.36, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 13.0% of the company shares are held by company insiders
Latest headline from finance.yahoo.com: Eupraxia Pharmaceuticals to Present at H.C. Wainwright BIOCONNECT Virtual Conference - Yahoo Finance
Continue to Investing Opportunities. Note that the Eupraxia Pharmaceuticals information on this page should be used as a complementary analysis to other Eupraxia Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Complementary Tools for Eupraxia OTC Stock analysis

When running Eupraxia Pharmaceuticals price analysis, check to measure Eupraxia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eupraxia Pharmaceuticals is operating at the current time. Most of Eupraxia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eupraxia Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Eupraxia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eupraxia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Is Eupraxia Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eupraxia Pharmaceuticals. If investors know Eupraxia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eupraxia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Eupraxia Pharmaceuticals is measured differently than its book value, which is the value of Eupraxia that is recorded on the company's balance sheet. Investors also form their own opinion of Eupraxia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eupraxia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eupraxia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eupraxia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eupraxia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Eupraxia Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eupraxia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.